LTFS
TPST icon

Ladenburg Thalmann Financial Services’s Tempest Therapeutics TPST Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed -$3K – 5203
2017
Q4 		$3K Buy
+1
New +$4.2K ﹤0.01% 4702
2015
Q2 		– Hold
0
– -$26K – 4755
2015
Q1 		– Hold
0
– – – 3026
2014
Q4 		– Hold
0
– – – 2643

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Ladenburg Thalmann Financial Services's TPST Position: Q1 2018 in Review

Ladenburg Thalmann Financial Services sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 1 share — an estimated $3K sold.

Ladenburg Thalmann Financial Services first reported a position in TPST in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 1 Tempest Therapeutics share in Q1 2018, an estimated $3K.
  • Ladenburg Thalmann Financial Services first reported a position in Tempest Therapeutics in Q4 2017 and held it in 1 quarter.
  • Ladenburg Thalmann Financial Services's Tempest Therapeutics position peaked at $3K in Q4 2017.
  • 41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2018, filed 15 May 2018.